Raymond James Initiates Coverage On Black Diamond Therapeutic with Outperform Rating, Announces Price Target of $20
Portfolio Pulse from Benzinga Newsdesk
Raymond James has initiated coverage on Black Diamond Therapeutic (NASDAQ:BDTX) with an Outperform rating and a price target of $20.
July 31, 2024 | 9:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Raymond James has initiated coverage on Black Diamond Therapeutic with an Outperform rating and a price target of $20.
The initiation of coverage with an Outperform rating and a price target of $20 by Raymond James is likely to positively impact the stock price of Black Diamond Therapeutic in the short term. Analyst ratings and price targets are significant indicators for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100